Your email has been successfully added to our mailing list.

×
0.113861386138614 0.118811881188119 0.252475247524753 0.252475247524753 0.277227722772277 0.292079207920792 0.341584158415842 0.408415841584159
Stock impact report

Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer

Celsion Corporation (CLSN) 
Last celsion corporation earnings: 11/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.celsion.com/investor-relations
Company Research Source: GlobeNewswire
86% Objective Response Rate (ORR) in Phase IB Dose Escalating Study 100% ORR and 100% R0 (Margin Negative) Surgical Resection Rate at Highest Dose Cohort Increased Ratio of CD8+ Cells to Immunosuppressive T-cells Observed in 75% of Patients Indicating a Shift to a Pro-Immune Stimulatory Environment LAWRENCEVILLE, N.J., July 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer followed by interval debulking surgery.  Enrollment Complete in the OVATION Study.  The last patient in the 4th dose cohort has completed their GEN-1 treatment which allows for a safety evaluation by the Company’s Data Safety Monitoring Board (DSMB) in mid-July.  The Company recently announced the latest clinical findings from the Show less Read more
Impact Snapshot
Event Time:
CLSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CLSN alerts
Opt-in for
CLSN alerts

from News Quantified
Opt-in for
CLSN alerts

from News Quantified